Filing Details

Accession Number:
0000902664-25-001335
Form Type:
13D Filing
Publication Date:
2025-03-03 19:00:00
Filed By:
VenBio Select Advisor
Company:
Whitehawk Therapeutics Inc. (NASDAQ:WHWK)
Filing Date:
2025-03-04
SEC Url:
13D Filing
Ownership Summary

Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
AVORO CAPITAL ADVISORS LLC 9,515,802 0 9,515,802 0 9,515,802 18.0%
AVORO VENTURES LLC 2,288,950 0 2,288,950 0 2,288,950 4.8%
BEHZAD AGHAZADEH 11,914,961 0 11,914,961 0 11,914,961 19.99%
Filing





If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox not checked

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






SCHEDULE 13D



Comment for Type of Reporting Person:
The amounts in rows (7), (9) and (11) include 6,666,400 shares of Common Stock issuable upon exercise of Pre-Funded Warrants. As more fully described in Item 5, the Pre-Funded Warrants are subject to the 19.99% Blocker (as defined in Item 5(a)) and the percentage set forth on row (13) gives effect to the 19.99% Blocker. The percentage set forth on row (13) and the number of shares of Common Stock set forth on rows (7), (9) and (11) reflect the full exercise of the Pre-Funded Warrants reported on this cover page; however, the ability to exercise such Pre-Funded Warrants at any given time is subject to the 19.99% Blocker which applies to the beneficial ownership of the Reporting Persons in the aggregate.


SCHEDULE 13D



Comment for Type of Reporting Person:
The amounts in rows (7), (9) and (11) include 1,666,600 shares of Common Stock issuable upon exercise of Pre-Funded Warrants. As more fully described in Item 5, Avoro Ventures beneficially owns Pre-Funded Warrants subject to the19.99% Blocker. The percentage set forth on row (13) and the number of shares of Common Stock set forth on rows (7), (9) and (11) reflect the full exercise of the Pre-Funded Warrants reported on this cover page; however, the ability to exercise such Pre-Funded Warrants at any given time is subject to the 19.99% Blocker which applies to the beneficial ownership of the Reporting Persons in the aggregate.


SCHEDULE 13D



Comment for Type of Reporting Person:
The amounts in rows (7), (9) and (11) include 110,209 shares of Common Stock underlying director stock options and 8,333,000 shares of Common Stock issuable upon exercise of Pre-Funded Warrants. As more fully described in Item 5, the Pre-Funded Warrants are subject to the 19.99% Blocker and the percentage set forth on row (13) gives effect to the 19.99% Blocker. However, rows (7), (9) and (11) show the number of shares of Common Stock that would be issuable upon the full exercise of the Pre-Funded Warrants and does not give effect to the 19.99% Blocker. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to the 19.99% Blocker, is less than the number of securities reported on rows (7), (9) and (11).


SCHEDULE 13D

 
AVORO CAPITAL ADVISORS LLC
 
Signature:/s/ Scott Epstein
Name/Title:Scott Epstein, Chief Operating Officer & Chief Compliance Officer
Date:03/04/2025
 
AVORO VENTURES LLC
 
Signature:/s/ Scott Epstein
Name/Title:Scott Epstein, Chief Operating Officer & Chief Compliance Officer
Date:03/04/2025
 
BEHZAD AGHAZADEH
 
Signature:/s/ Behzad Aghazadeh
Name/Title:Behzad Aghazadeh, Individually
Date:03/04/2025